PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis.

ABSTRACT:

Objective

Pulmonary hypertension (PH) in context with interstitial lung disease (ILD) portends serious clinical consequences and a high rate of mortality. Recently published randomized controlled trials (RCTs) which assessed the pulmonary arterial hypertension (PAH)-specific drugs for pulmonary hypertension and interstitial lung disease (PH-ILD) revealed inconsistent clinical outcomes with previous studies. We conducted a systemic review and meta-analysis to further investigate the effect of PAH-specific therapies for PH-ILD.

Methods

Clinical trials were searched from the EMBASE, PUBMED, and CENTRAL databases. The duration from the establishment of the database to June 2022 for RCTs evaluates the effect of PAH-specific therapy in patients with PH-ILD. RevMan 5.4 was used for

SUBMITTER: Zhao N 

PROVIDER: S-EPMC9713234 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature